A very expensive drug that’s proven effective in the management of a rare form of Cystic Fibrosis is now included in Nova Scotia’s Pharmacare programs.
As of October 1, Kalydeco will be available to patients with Cystic Fibrosis who are six years old and up and carry a specific gene, G551D.
On average, the Kalydeco costs about $300,000 a year per patient.
There are eight Nova Scotians eligible for the coverage.
